The manufacturer was informed of the following event through mantra study database.Reportedly, a perceval plus valve size xl was implanted in the patient on (b)(6)2022.Based on the information received, patient had paravalvular regurgitation that started on (b)(6) 2023.The patient was hospitalized for evaluation of pvl identified in tte conducted on (b)(6) 2023, and discharged after examination.The event severity was considered mild, and no action has yet been taken.As reported, patient's clinical history included angina; systemic hypertension; dyslipidemia; obesity; tympanites (50 years ago); and patient was nyha class iii.
|
A complete manufacturing and material records review for the sutureless valve pvf-xl has been performed.The results confirmed that the device satisfied all material, visual and performance standards required at the time of manufacture and release.Based on the limited information available, the definitive root cause of the reported event cannot be established at this time.However, from the document review performed, no manufacturing deficiencies were noted.Based on the information available, no action has yet been taken and the valve remained implanted.As such, further investigation on the actual device cannot be performed either.Should further information be received in the future, a follow up report will be provided.
|